What does ImageneBio, Inc. do?
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor…
What is ImageneBio, Inc.'s P/E and P/B ratio?
ImageneBio, Inc. has a P/E ratio of -1.0 and a P/B ratio of 0.32.
What is ImageneBio, Inc.'s debt-to-equity ratio?
ImageneBio, Inc. has a debt-to-equity ratio of 0.01.
How much does ImageneBio, Inc. owe compared with what it owns?
ImageneBio, Inc. owes $0.07 for every $1 it owns (balance sheet Jun 2026), which is low.
What is ImageneBio, Inc.'s Positivity rank?
ImageneBio, Inc. is ranked #1,829 of 6,774 companies globally and #463 of 4,000 in United States on PositoAI, with a Positivity Score of 22,249.
Does ImageneBio, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for ImageneBio, Inc..
Where can I read the latest news about ImageneBio, Inc.?
Recent headlines about ImageneBio, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does ImageneBio, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of ImageneBio, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.